萨库比特里尔/瓦尔萨坦与ACE抑制剂或ARBs:随机试验的系统审查和元分析
Endurance Evbayekha1, Abiodun Benjamin Idowu2, Shane LaRue1
1St. Luke's Hospital, Chesterfield, Missouri, USA.
JACC. Advances
|February 19, 2025
概括
萨库比特里尔/瓦尔萨坦 (SAV) 减少了心力衰竭在喷射小部分 (EF) 的再入院. 然而,它只能降低EF≤40%的患者的全因死亡率,对心血管死亡率没有显著影响.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 萨库比特里尔/瓦尔萨坦 (SAV) 是心力衰竭 (HF) 的关键治疗方法.
- 以前的试验表明,SAV在减少NT-proBNP方面优于ACEI/ARBs.
- 关于SAV对死亡率和再入院等硬临床终点的影响,存在不同的结果.
研究的目的:
- 在接受SAV治疗的HF患者中评估硬终点,与ACEI/ARBs对比.
- 与ACEI/ARB相比,对SAV进行全面的风险效益分析.
主要方法:
- 随机临床试验 (RCT) 的系统审查和元分析,截至2023年11月.
- 包括14个RCT与25167名参与者,将SAV与ACEI或ARB进行比较.
- 用随机效应模型和风险比率分析了全因死亡率,心血管死亡率和HF再住院情况.
主要成果:
- 在所有射出分数 (EF) 级别 (RR:0.85) 中,SAV显著减少了HF再入院.
- 在EF≤40% (RR:0.88) 的患者中,SAV降低了全因死亡率,但在EF>40% (RR:0.97) 的患者中没有降低.
- 在SAV和ACEI/ARB组之间没有观察到心血管死亡率的显著差异 (RR:0.9).
结论:
- 不管EF,SAV在减少HF再入院方面显示出显著的好处.
- 用SAV减少所有原因的死亡率仅限于EF降低 (≤40%) 的患者.
- 在降低心血管死亡率方面,SAV与ACEI/ARB相比没有显著的优势.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
371
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
573
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
573
01:25Antihypertensive Drugs: Direct Renin Inhibitors
474
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
474
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
457
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
457
01:33Hormonal Regulation
32.8K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
441
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
441